Oncology – Exam 3 Study Guide (Melanoma,
Lymphoma, TBL) with Key Concepts and Practice
Questions
Adjuvant tx in resected stage 3 melanoma with BRAF wild type
2 drugs and tx length - correct answer ✔✔ PD-1 inhibitor for 1 years
Nivolumab or Pembrolizumab x52 weeks
Adjuvant tx in resected stage 3 melanoma with BRAF V600E/K mutation
2 drugs + another combo agent - correct answer ✔✔ Nivolumab or Pembrolizumab x52 weeks
Dabrafenib + Trametinib
T/F: Ipilimumab is standard of care for patients with resected stage 3 melanoma - correct
answer ✔✔ False! No longer considered to be a standard-of-care after recent advances with
anti-PD-1 and BRAF targeted therapies
Nivolumab Drug class
and FDA indication - correct answer ✔✔ Anti-PD inhibitor
adjuvant treatment in melanoma with lymph nodes involvement or metastatic disease with
complete resection.
, Pembrolizumab (Keytruda)
Drug Class
Indications - correct answer ✔✔ PD-L1 inhibitor
completely resected, stage IIIA (>1 mm lymph node metastasis), IIIB or IIIC melanoma
BRAF mutated resectable stage IIIA-C melanoma
what therapy do we use? - correct answer ✔✔ Combined BRAF and MEK Inhibition:
Dabrafenib 150 mg bid + trametinib 2 mg daily for 1 year
ASCO guidelines for Adjuvant therapy in resected stage IV melanoma - correct answer ✔✔
Nivolumab (strong)
Pembrolizumab or dabrafenib + trametinib (if BRAF V600E/K mutation) (weak)
ASCO guidlines:· Unresectable/metastatic melanoma if BRAF wild type - correct answer ✔✔
Ipilimumab + nivolumab followed by nivolumab
Nivolumab or pembrolizumab
ASCO guidlines:· Unresectable/metastatic melanoma if BRAF V600 mutation - correct answer
✔✔ Ipilimumab + nivolumab followed by nivolumab
Lymphoma, TBL) with Key Concepts and Practice
Questions
Adjuvant tx in resected stage 3 melanoma with BRAF wild type
2 drugs and tx length - correct answer ✔✔ PD-1 inhibitor for 1 years
Nivolumab or Pembrolizumab x52 weeks
Adjuvant tx in resected stage 3 melanoma with BRAF V600E/K mutation
2 drugs + another combo agent - correct answer ✔✔ Nivolumab or Pembrolizumab x52 weeks
Dabrafenib + Trametinib
T/F: Ipilimumab is standard of care for patients with resected stage 3 melanoma - correct
answer ✔✔ False! No longer considered to be a standard-of-care after recent advances with
anti-PD-1 and BRAF targeted therapies
Nivolumab Drug class
and FDA indication - correct answer ✔✔ Anti-PD inhibitor
adjuvant treatment in melanoma with lymph nodes involvement or metastatic disease with
complete resection.
, Pembrolizumab (Keytruda)
Drug Class
Indications - correct answer ✔✔ PD-L1 inhibitor
completely resected, stage IIIA (>1 mm lymph node metastasis), IIIB or IIIC melanoma
BRAF mutated resectable stage IIIA-C melanoma
what therapy do we use? - correct answer ✔✔ Combined BRAF and MEK Inhibition:
Dabrafenib 150 mg bid + trametinib 2 mg daily for 1 year
ASCO guidelines for Adjuvant therapy in resected stage IV melanoma - correct answer ✔✔
Nivolumab (strong)
Pembrolizumab or dabrafenib + trametinib (if BRAF V600E/K mutation) (weak)
ASCO guidlines:· Unresectable/metastatic melanoma if BRAF wild type - correct answer ✔✔
Ipilimumab + nivolumab followed by nivolumab
Nivolumab or pembrolizumab
ASCO guidlines:· Unresectable/metastatic melanoma if BRAF V600 mutation - correct answer
✔✔ Ipilimumab + nivolumab followed by nivolumab
